Загрузка...
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical antiviral properties of LDV, including in vitro potency, in vitro resistance profile, and activit...
Сохранить в:
Опубликовано в: : | Antimicrob Agents Chemother |
---|---|
Главные авторы: | , , , , , , , , , , , , , , , , |
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
American Society for Microbiology
2016
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4775926/ https://ncbi.nlm.nih.gov/pubmed/26824950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02524-15 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|